Investigating how cannabidiol interacts with tacrolimus in organ transplant patients
Drug-gene-nutraceutical interactions of cannabidiol
This study is looking at how cannabidiol (CBD) might affect the way your body processes tacrolimus, a medication you take after an organ transplant, and it aims to help doctors figure out the best dosages for patients based on their unique genetics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11009518 on NIH RePORTER |
What this research studies
This research focuses on understanding the safety and interactions between cannabidiol (CBD) and tacrolimus, a medication commonly prescribed to organ transplant recipients. The study will explore how different genetic variations in the CYP3A5 enzyme affect the metabolism of these drugs. By conducting pharmacokinetic studies, researchers aim to determine if CBD alters the effectiveness of tacrolimus, which could lead to necessary adjustments in medication dosages for patients. The findings may provide insights into personalized treatment approaches for transplant patients using CBD.
Who could benefit from this research
Good fit: Ideal candidates for this research include organ transplant recipients who are prescribed tacrolimus and are considering or currently using cannabidiol.
Not a fit: Patients who are not organ transplant recipients or those not taking tacrolimus are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective medication regimens for organ transplant recipients who use cannabidiol.
How similar studies have performed: Previous research has shown promising results in understanding drug interactions involving cannabidiol, but this specific investigation into tacrolimus is relatively novel.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Eadon, Michael Thomas — Indiana University Indianapolis
- Study coordinator: Eadon, Michael Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.